Patrick Morris
National Institutes of Health
7 Papers
36 Citations
Patrick Morris is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Allosteric regulation & GABAA receptor. The author has an hindex of 2, co-authored 7 publications. Previous affiliations of Patrick Morris include University of Maryland, Baltimore.
Chat about Author
Papers
NMDAR inhibition-independent antidepressant actions of ketamine
Ruin Moaddel,Patrick Morris,Polymnia Georgiou,Jonathan Fischell,Manickavasagom Alkondon,Peixiong Yuan,J. Pribut,Simranjit X. Singh,Katina Sylvestre S. Dossou,Yuhong Fang,W. Wainer,Edson X. Albuquerque,Scott M. Thompson,A. Zarate,D. Gould +14 more
- 01 Jan 2016
24
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo
Courtney L. Finch,Julie Dyall,Shuang Xu,Elizabeth A. Nelson,Elena Postnikova,Janie Y. Liang,Huanying Zhou,Lisa Evans DeWald,Craig J. Thomas,Amy Wang,Xin Xu,Emma Hughes,Patrick Morris,Jon C. Mirsalis,Linh H. Nguyen,Maria P. Arolfo,Bryan Koci,Michael R. Holbrook,Lisa E. Hensley,Peter B. Jahrling,Connie S. Schmaljohn,Lisa M. Johansen,Gene G. Olinger,Joshua T. Schiffer,Judith M. White +24 more
- 10 Mar 2021
TL;DR: In this article, the authors proposed a cocktail containing orally available and room temperature stable drugs with strong activity against multiple filoviruses, such as EBOV, for more facile and cost-effective management of EVD.
13
Patent
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
Irving Wainer,Carlos A. Zarate,Ruin Moaddel,Todd D. Gould,Panos Zanos,Craig Thomas,Patrick Morris +6 more
- 27 Mar 2017
TL;DR: In this paper, a method of treating psychotic depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced depression, Depressive disorder due to another medical condition, Other Specified Depressive disorders, Unspecified depression disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety
4
Patent
Process for synthesis and purification of (2R,6R)-hydroxynorketamine
Craig Thomas,Patrick Morris,Castledine Richard Andrew,Bourne Samuel Lawrence +3 more
- 07 Jan 2021
TL;DR: In this paper, a process for the preparation of (2R, 6R)-hydroxynorketamine is provided. But the process requires no chromatography purification and affords the (2 R, 6 R)-hydoxide in eight steps with a 26% overall yield and greater than 97% purity.
Patent
Formes cristallines et procédés de synthèse de (2r,6r)-hydroxynorkétamine et de (2s,6s)-hydroxynorkétamine
Craig Thomas,Patrick Morris,Carlos A. Zarate,Ruin Moaddel,Todd D. Gould,Panos Zanos +5 more
- 27 Mar 2017
TL;DR: The authors concerne un procede de synthese de formes de base libre de (2R, 6R)-hydroxynorketamine (HNK) and de ( 2S, 6S)-hydronylkarnetamine correspondants.